Two Democratic congressmen are raising questions about whether Mylan NV, the company facing backlash for raising the price of its EpiPen device, overcharged the government's Medicaid program for the allergy treatment.

ADVERTISEMENT

Sen. Ron Wyden Ronald (Ron) Lee WydenGOP set to release controversial Biden report Democrats fear Russia interference could spoil bid to retake Senate GOP senator blocks Schumer resolution aimed at Biden probe as tensions run high MORE (D-Ore.) and Rep. Frank Pallone (D-N.J.) wrote a letter to the secretary of Department of Health and Human Services asking for clarification on whether EpiPen was considered a generic, "non-innovator" drug, or a brand-name drug by the Medicaid program, according to Reuters.

Current law states that branded drugs and generic drugs available from a single source must pay a rebate amount of at least 23.1 percent of the average manufacturer price, while generic drugs are subject to a 13 percent rebate, according to Reuters.

Mylan said in a statement to Reuters that it has complied with all laws and regulations regarding the rebates.

Mylan announced this week it would reduce the price of the device after an uproar in Washington.

It will provide a savings card worth up to $300 for people who have been paying the full price out-of-pocket, effectively reducing the cost by 50 percent.